CO2021017173A2 - Inhibidor de egfr para el tratamiento de cáncer - Google Patents

Inhibidor de egfr para el tratamiento de cáncer

Info

Publication number
CO2021017173A2
CO2021017173A2 CONC2021/0017173A CO2021017173A CO2021017173A2 CO 2021017173 A2 CO2021017173 A2 CO 2021017173A2 CO 2021017173 A CO2021017173 A CO 2021017173A CO 2021017173 A2 CO2021017173 A2 CO 2021017173A2
Authority
CO
Colombia
Prior art keywords
cancer treatment
egfr inhibitor
cancer
ring
treatment
Prior art date
Application number
CONC2021/0017173A
Other languages
English (en)
Inventor
Antonio Ricci
Daniel Rueher
Sandra Steiner
Cosimo Dolente
Annick Goergler
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
David Hewings
Ulrike Obst-Sander
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2021017173A2 publication Critical patent/CO2021017173A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La solicitud se refiere a un compuesto de fórmula (I) que contiene un anillo tiazol, un anillo indazol y un sistema de anillo 6,7-dihidro-5H-pirrolo[1,2-c]imidazol, a las composiciones farmacéuticas que lo contienen y a su uso médico. Los compuestos se describen como inhibidores alostéricos selectivos de T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S que contienen mutantes de EGFR y, de este modo, son útiles para el tratamiento de cáncer, en particular, cáncer de pulmón no microcítico.
CONC2021/0017173A 2019-06-21 2021-12-15 Inhibidor de egfr para el tratamiento de cáncer CO2021017173A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21
PCT/EP2020/067076 WO2020254562A1 (en) 2019-06-21 2020-06-19 Egfr inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
CO2021017173A2 true CO2021017173A2 (es) 2022-01-17

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017173A CO2021017173A2 (es) 2019-06-21 2021-12-15 Inhibidor de egfr para el tratamiento de cáncer

Country Status (28)

Country Link
US (4) US20220315592A1 (es)
EP (4) EP3986895B1 (es)
JP (4) JP2022537191A (es)
KR (1) KR20220024105A (es)
CN (4) CN113993873A (es)
AR (4) AR119210A1 (es)
AU (1) AU2020295703A1 (es)
BR (1) BR112021025445B1 (es)
CA (1) CA3140485A1 (es)
CL (1) CL2021003408A1 (es)
CO (1) CO2021017173A2 (es)
CR (1) CR20210624A (es)
DK (1) DK3986897T3 (es)
ES (1) ES2961187T3 (es)
FI (1) FI3986897T3 (es)
HR (1) HRP20231276T1 (es)
HU (1) HUE063676T2 (es)
IL (1) IL288522A (es)
LT (1) LT3986897T (es)
MA (1) MA56508B1 (es)
MX (1) MX2021015464A (es)
PE (1) PE20220576A1 (es)
PL (1) PL3986897T3 (es)
PT (1) PT3986897T (es)
RS (1) RS64720B1 (es)
SI (1) SI3986897T1 (es)
TW (4) TW202115072A (es)
WO (4) WO2020254568A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217924A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer
WO2023217923A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag New indazole derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
US20110212078A1 (en) 2008-06-25 2011-09-01 Reddy Panduranga Adulla P Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
JP6639497B2 (ja) * 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
CN107848964B (zh) 2015-05-14 2021-03-19 威斯塔解剖学和生物学研究所 Ebna1抑制剂和使用其的方法
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
KR20210025535A (ko) * 2018-06-29 2021-03-09 에프. 호프만-라 로슈 아게 화합물

Also Published As

Publication number Publication date
EP3986897A1 (en) 2022-04-27
MA56508A (fr) 2022-04-27
FI3986897T3 (fi) 2023-10-20
TW202115053A (zh) 2021-04-16
HRP20231276T1 (hr) 2024-02-02
EP3986898B1 (en) 2023-03-15
PE20220576A1 (es) 2022-04-20
TW202115074A (zh) 2021-04-16
WO2020254565A1 (en) 2020-12-24
JP2022537769A (ja) 2022-08-29
LT3986897T (lt) 2023-11-10
WO2020254562A1 (en) 2020-12-24
EP3986898A1 (en) 2022-04-27
AU2020295703A1 (en) 2022-01-06
CN113993872A (zh) 2022-01-28
TW202115072A (zh) 2021-04-16
TW202115071A (zh) 2021-04-16
US20220315593A1 (en) 2022-10-06
JP2022537191A (ja) 2022-08-24
CN113993873A (zh) 2022-01-28
US20220135571A1 (en) 2022-05-05
AR119210A1 (es) 2021-12-01
PT3986897T (pt) 2023-10-23
SI3986897T1 (sl) 2023-12-29
KR20220024105A (ko) 2022-03-03
CN113966335A (zh) 2022-01-21
RS64720B1 (sr) 2023-11-30
CA3140485A1 (en) 2020-12-24
AR119209A1 (es) 2021-12-01
WO2020254568A1 (en) 2020-12-24
ES2961187T3 (es) 2024-03-08
US20220315592A1 (en) 2022-10-06
WO2020254572A1 (en) 2020-12-24
CN114008049A (zh) 2022-02-01
JP2022538055A (ja) 2022-08-31
MA56508B1 (fr) 2023-11-30
BR112021025445A2 (pt) 2022-02-01
JP2022538403A (ja) 2022-09-02
MX2021015464A (es) 2022-01-24
AR119208A1 (es) 2021-12-01
DK3986897T3 (da) 2023-10-30
EP3986895A1 (en) 2022-04-27
EP3986897B1 (en) 2023-08-30
BR112021025445B1 (pt) 2024-02-27
IL288522A (en) 2022-01-01
CR20210624A (es) 2022-02-14
PL3986897T3 (pl) 2024-01-22
EP3986895B1 (en) 2023-03-15
HUE063676T2 (hu) 2024-01-28
CL2021003408A1 (es) 2022-10-14
AR119206A1 (es) 2021-12-01
EP3986896B1 (en) 2023-03-15
US20230054473A1 (en) 2023-02-23
EP3986896A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CO2021017173A2 (es) Inhibidor de egfr para el tratamiento de cáncer
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2021002995A1 (es) (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
BR112021022897A2 (pt) Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo
CL2011001360A1 (es) Compuestos derivados de imidazol[1,2-a]pirazin-8-amina, inhibidores de tirosina quinasa esplenica; composicion farmaceutica que comprende un compuesto; uso de los compuestos en la preparacion de medicamentos para el tratamiento de trastornos alergicos, enfermedades autoinmunes y enfermedades inflamatorias; y metodo in vitro.
UY38742A (es) Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
GT201000172A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
DOP2017000188A (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
EA201591904A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
DOP2022000130A (es) Derivados de benzimidazol